West Paces Advisors’s DexCom DXCM Stock Holding History

West Paces Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-72	Closed	-$4.92K	–	310
2025 Q1	$4.92K	Hold	72	–	–	﹤0.01%	386
2024 Q4	$5.6K	Hold	72	–	–	﹤0.01%	381
2024 Q3	$4.83K	Hold	72	–	–	﹤0.01%	386
2024 Q2	$8.16K	Hold	72	–	–	﹤0.01%	368
2024 Q1	$9.99K	Sell	72 -4	-5%	-$503	﹤0.01%	360
2023 Q4	$9.43K	Buy	76 +4	+6%	+$409	﹤0.01%	369
2023 Q3	$6.72K	Hold	72	–	–	﹤0.01%	374
2023 Q2	$9.25K	Hold	72	–	–	﹤0.01%	374
2023 Q1	$8.37K	Hold	72	–	–	﹤0.01%	381
2022 Q4	$8.15K	Hold	72	–	–	﹤0.01%	371
2022 Q3	$5.8K	Hold	72	–	–	﹤0.01%	381
2022 Q2	$5.37K	Hold	72	–	–	﹤0.01%	402
2022 Q1	$9.21K	Hold	72	–	–	﹤0.01%	374
2021 Q4	$9.66K	Hold	72	–	–	﹤0.01%	380
2021 Q3	$9.84K	Sell	72 -160	-69%	-$20.2K	﹤0.01%	360
2021 Q2	$24.8K	Hold	232	–	–	0.01%	269
2021 Q1	$20.8K	Buy	232 +160	+222%	+$15K	0.01%	264
2020 Q4	$6.66K	Hold	72	–	–	﹤0.01%	345
2020 Q3	$7.42K	Hold	72	–	–	﹤0.01%	329
2020 Q2	$7.3K	Hold	72	–	–	﹤0.01%	340
2020 Q1	$4.85K	Buy	+72	New	+$4.48K	﹤0.01%	367

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

West Paces Advisors's DXCM Position: Q2 2025 in Review

West Paces Advisors sold out of DexCom (DXCM) in Q2 2025, closing a stake of 72 shares — an estimated $4.92K sold.

West Paces Advisors first reported a position in DXCM in Q1 2020 and held it in 21 quarters. The position peaked at $24.8K in Q2 2021. 939 funds tracked by Wall St. Rank hold DXCM as of Q2 2025.

West Paces Advisors reported no remaining DexCom position as of Q2 2025 after selling out during the quarter.
West Paces Advisors sold 72 DexCom shares in Q2 2025, an estimated $4.92K.
West Paces Advisors first reported a position in DexCom in Q1 2020 and held it in 21 quarters.
West Paces Advisors's DexCom position peaked at $24.8K in Q2 2021.
939 funds tracked by Wall St. Rank held DexCom as of Q2 2025.

Based on West Paces Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.